Merck & Company News - June 25, 2026

🟢 MRK is trading 3.2% up today on EU approval for Keytruda bladder cancer combo

MRK is trading 3.2% up at $124.40 after winning a key European regulatory approval for its oncology portfolio. • The European Commission cleared the...

Merck Secures EU Approval for Keytruda Combo, First-of-Its-Kind Bladder Cancer Treatment

The European Commission approved Merck’s anti-PD-1 therapy, Keytruda, in combination with Padcev. The regimen treats adult patients with resectable...